<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapeutic <z:hpo ids='HP_0002045'>hypothermia</z:hpo> (TH) is a process of cooling a patient post <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo>/<z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo> to 32-34 degrees C for 24 hours </plain></SENT>
<SENT sid="1" pm="."><plain>This improves neurological outcome and is part of current guidelines </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0002045'>Hypothermia</z:hpo> prolongs QT interval, which can precipitate <z:hpo ids='HP_0001664'>torsades de pointes</z:hpo> (TdP) </plain></SENT>
<SENT sid="3" pm="."><plain>We performed a retrospective review of <z:hpo ids='HP_0000001'>all</z:hpo> patients who received TH in our hospital over a period of 2 years to assess the effect of TH on the corrected OT interval (QTc) and any possible pro-<z:hpo ids='HP_0011675'>arrhythmia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>A total of 13 patients received TH </plain></SENT>
<SENT sid="5" pm="."><plain>QTc prolonged in <z:hpo ids='HP_0000001'>all</z:hpo> patients with an average of 80.3 + 57.2 ms., and up to 109.8 + 80.4 ms in patients who received <z:chebi fb="0" ids="2663">Amiodarone</z:chebi> concurrently </plain></SENT>
<SENT sid="6" pm="."><plain>No TdP was seen in any patient </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that TH is safe, though careful monitoring of the OTc interval is advisable especially with concurrent use of QT prolonging drugs </plain></SENT>
</text></document>